<DOC>
	<DOCNO>NCT01379482</DOCNO>
	<brief_summary>The aim study investigate whether multimodal treatment peritoneal carcinomatosis gastric cancer feasible evaluate clinical outcome clinical effectiveness neoadjuvant systemic chemotherapy follow cytoreductive surgery + hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy , compare systemic chemotherapy , patient peritoneal carcinomatosis gastric cancer .</brief_summary>
	<brief_title>Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo Peritoneal Carcinomatosis From Gastric Cancer</brief_title>
	<detailed_description>Between January 2005 March 2009 , 18 consecutive patient PC gastric cancer schedule neoadjuvant systemic chemotherapy follow CRS+HIPEC+EPIC Uppsala University Hospital , Uppsala , Sweden . The regional ethic committee approve study inform consent obtain patient study register ClinicalTrials.gov , identifier NCT01379482 . The eligibility requirement treatment : histologically confirm diagnosis primary gastric adenocarcinoma ; histologically radiologically confirmed PC diagnosis ; distant metastasis ; adequate renal , haematopoietic liver function , Karnofsky performance status ( KPS ) &gt; 70 . Table 1 summarises demographic basic clinical patient data . Patients Eighteen patient ( eight female ten male ) , median age 57 year ( range 38-74 ) , include study . Treatment begin three month ' ( range 2-4.5 ) neoadjuvant systemic chemotherapy . Four week receive last course chemotherapy , patient clinical radiological sign tumour progression underwent laparotomy preparation CRS+HIPEC follow EPIC five day . Patients clinical radiological sign tumour progression neoadjuvant systemic chemotherapy undergo plan loco-regional treatment continue palliative systemic chemotherapy discretion physician charge patient . Neoadjuvant chemotherapy The intention treat patient combination chemotherapy three month . The choice chemotherapy individualise , patient receive optimal drug combination suitable good performance patient metastatic gastric cancer . Routine clinical control blood sample do every treatment cycle . In order rule patient progressive disease distant metastasis , abdominal thoracic CT scan evaluation perform prior surgery . Surgical treatment Depending disease extent , CRS perform described Sugarbaker . Immediately postoperatively , tumour load completeness cytoreduction PC record use Peritoneal Cancer Index ( PCI ) [ 12 ] Completeness Cytoreduction score ( CC ) respectively . The PCI ( range 1-39 ) consist lesion size score 13 different region abdomen : 0=no tumour see , 1=tumour 0.5 cm , 2=tumour 5 cm 3=tumour &gt; 5 cm . The PCI score calculate add together lesion size score 13 region . The CC score base upon size tumour leave cytoreduction : CC0=no peritoneal seed visible , CC1=nodules 2.5 mm , CC2=nodules 2.5 cm CC3=nodules &gt; 2.5 cm . HIPEC EPIC HIPEC administer accord Coliseum technique combine EPIC five day . Before perfusion , patient 's body temperature lower 35°C cool blanket ( Allon® ) . The intra-abdominal temperature perfusion range 42°C 44°C . Four intra-abdominal drain leave place surgery EPIC give daily first five postoperative day . Tumour marker , histopathology adverse event Five serum tumour marker ( CEA , CA 125 , CA 19-9 , CA 15-3 CA 72-4 ) take one six day surgery ten day surgery , analyse frequency impact gastric cancer PC tumour marker . The sixth edition TNM classification use . The presence signet ring cell grade differentiation accord Lauren 's classification report . Therapy-related adverse event grade accord National Cancer Institute 's common toxicity criterion ( NCI-CTC ) version 3.0 . OS calculate patient date first neoadjuvant chemotherapy . Statistical method All analysis perform basis intention-to-treat . OS disease-free survival ( DFS ) analyse patient treated CC0 . Results present median , 95 % confidence interval ( CI ) . A P-value le 0.05 consider statistically significant . The computer software package STATISTICA AXA version 10.0 , StatSoft Scandinavia , Sweden , use statistical evaluation survival data .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologically confirm diagnosis primary gastric cancer + histologically and/or radiologically confirm peritoneal carcinomatosis diagnosis Adequate renal , hematopoietic liver function WHO performance status ( WHO ) &lt; 2 . Distant metastasis Surgically resectable lymphnode metastasis Contraindication chemotherapy treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Peritoneal carcinomatosis gastric cancer</keyword>
</DOC>